Colivelin prolongs survival of an ALS model mouse

Tomohiro Chiba, Marina Yamada, Jumpei Sasabe, Kenzo Terashita, Sadakazu Aiso, Masaaki Matsuoka, Ikuo Nishimoto

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disease for which there is no sufficiently effective therapy. We have reported in our earlier study that intracerebroventricular (i.c.v.) injection of activity-dependent neurotrophic factor (ADNF) improves motor performance of G93A-SOD1 transgenic mice without significant prolongation in survival. Here, we found that i.c.v. injection of a synthetic hybrid peptide named Colivelin composed of ADNF and AGA-(C8R)HNG17, a potent derivative of Humanin that is a bioactive peptide with anti-Alzheimer's disease activity, dose-dependently improved motor performance and prolonged survival of ALS mice. Histological analysis, performed at the age of 120 days, demonstrated increased motoneuronal survival in spinal cords of Colivelin-treated mice as compared with saline- or ADNF-treated mice, indicating that Colivelin is a promising neurotrophic peptide for treatment of ALS.

Original languageEnglish
Pages (from-to)793-798
Number of pages6
JournalBiochemical and Biophysical Research Communications
Volume343
Issue number3
DOIs
Publication statusPublished - 2006 May 12
Externally publishedYes

Fingerprint

Peptides
Neurons
Derivatives
activity-dependent neurotrophic factor
Colivelin

Keywords

  • ADNF
  • ALS
  • Colivelin
  • Humanin
  • Neuroprotection
  • SOD1

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Molecular Biology

Cite this

Chiba, T., Yamada, M., Sasabe, J., Terashita, K., Aiso, S., Matsuoka, M., & Nishimoto, I. (2006). Colivelin prolongs survival of an ALS model mouse. Biochemical and Biophysical Research Communications, 343(3), 793-798. https://doi.org/10.1016/j.bbrc.2006.02.184

Colivelin prolongs survival of an ALS model mouse. / Chiba, Tomohiro; Yamada, Marina; Sasabe, Jumpei; Terashita, Kenzo; Aiso, Sadakazu; Matsuoka, Masaaki; Nishimoto, Ikuo.

In: Biochemical and Biophysical Research Communications, Vol. 343, No. 3, 12.05.2006, p. 793-798.

Research output: Contribution to journalArticle

Chiba, T, Yamada, M, Sasabe, J, Terashita, K, Aiso, S, Matsuoka, M & Nishimoto, I 2006, 'Colivelin prolongs survival of an ALS model mouse', Biochemical and Biophysical Research Communications, vol. 343, no. 3, pp. 793-798. https://doi.org/10.1016/j.bbrc.2006.02.184
Chiba, Tomohiro ; Yamada, Marina ; Sasabe, Jumpei ; Terashita, Kenzo ; Aiso, Sadakazu ; Matsuoka, Masaaki ; Nishimoto, Ikuo. / Colivelin prolongs survival of an ALS model mouse. In: Biochemical and Biophysical Research Communications. 2006 ; Vol. 343, No. 3. pp. 793-798.
@article{099be957709f4cffbc27929f32379748,
title = "Colivelin prolongs survival of an ALS model mouse",
abstract = "Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disease for which there is no sufficiently effective therapy. We have reported in our earlier study that intracerebroventricular (i.c.v.) injection of activity-dependent neurotrophic factor (ADNF) improves motor performance of G93A-SOD1 transgenic mice without significant prolongation in survival. Here, we found that i.c.v. injection of a synthetic hybrid peptide named Colivelin composed of ADNF and AGA-(C8R)HNG17, a potent derivative of Humanin that is a bioactive peptide with anti-Alzheimer's disease activity, dose-dependently improved motor performance and prolonged survival of ALS mice. Histological analysis, performed at the age of 120 days, demonstrated increased motoneuronal survival in spinal cords of Colivelin-treated mice as compared with saline- or ADNF-treated mice, indicating that Colivelin is a promising neurotrophic peptide for treatment of ALS.",
keywords = "ADNF, ALS, Colivelin, Humanin, Neuroprotection, SOD1",
author = "Tomohiro Chiba and Marina Yamada and Jumpei Sasabe and Kenzo Terashita and Sadakazu Aiso and Masaaki Matsuoka and Ikuo Nishimoto",
year = "2006",
month = "5",
day = "12",
doi = "10.1016/j.bbrc.2006.02.184",
language = "English",
volume = "343",
pages = "793--798",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Colivelin prolongs survival of an ALS model mouse

AU - Chiba, Tomohiro

AU - Yamada, Marina

AU - Sasabe, Jumpei

AU - Terashita, Kenzo

AU - Aiso, Sadakazu

AU - Matsuoka, Masaaki

AU - Nishimoto, Ikuo

PY - 2006/5/12

Y1 - 2006/5/12

N2 - Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disease for which there is no sufficiently effective therapy. We have reported in our earlier study that intracerebroventricular (i.c.v.) injection of activity-dependent neurotrophic factor (ADNF) improves motor performance of G93A-SOD1 transgenic mice without significant prolongation in survival. Here, we found that i.c.v. injection of a synthetic hybrid peptide named Colivelin composed of ADNF and AGA-(C8R)HNG17, a potent derivative of Humanin that is a bioactive peptide with anti-Alzheimer's disease activity, dose-dependently improved motor performance and prolonged survival of ALS mice. Histological analysis, performed at the age of 120 days, demonstrated increased motoneuronal survival in spinal cords of Colivelin-treated mice as compared with saline- or ADNF-treated mice, indicating that Colivelin is a promising neurotrophic peptide for treatment of ALS.

AB - Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disease for which there is no sufficiently effective therapy. We have reported in our earlier study that intracerebroventricular (i.c.v.) injection of activity-dependent neurotrophic factor (ADNF) improves motor performance of G93A-SOD1 transgenic mice without significant prolongation in survival. Here, we found that i.c.v. injection of a synthetic hybrid peptide named Colivelin composed of ADNF and AGA-(C8R)HNG17, a potent derivative of Humanin that is a bioactive peptide with anti-Alzheimer's disease activity, dose-dependently improved motor performance and prolonged survival of ALS mice. Histological analysis, performed at the age of 120 days, demonstrated increased motoneuronal survival in spinal cords of Colivelin-treated mice as compared with saline- or ADNF-treated mice, indicating that Colivelin is a promising neurotrophic peptide for treatment of ALS.

KW - ADNF

KW - ALS

KW - Colivelin

KW - Humanin

KW - Neuroprotection

KW - SOD1

UR - http://www.scopus.com/inward/record.url?scp=33645944367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645944367&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2006.02.184

DO - 10.1016/j.bbrc.2006.02.184

M3 - Article

VL - 343

SP - 793

EP - 798

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 3

ER -